Has Lisa Beck, MD received payments from drug or device companies?

Yes. Drug and device makers reported $754,734 in general payments to Lisa Beck, MD across 352 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lisa Beck, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lisa Beck, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lisa Beck, MD

Dermatology · Rochester, NYNPI 1780649681

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $565,400 of the $754,734 with a category attached, or 74.9%. 28 manufacturers reported payments, led by Sanofi at 41.2% of the total. Reporting peaked in 2024 at $181,440 and has fallen 74.4% since, to $46,525 in 2025. Among dermatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$754,734in general payments, 2019–2025

Across 352 payments — averaging $2144.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$311K
LEO Pharma AS$86K
Sanofi-aventis U.S. LLC$84K
AbbVie$28K
UCB, Inc.$25K
Regeneron$24K
plus $197K from 22 others

$1,711,192in research payments, 2019–2025

Across 622 payments — averaging $2751.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$627K
Regeneron$499K
Kiniksa Pharmaceuticals, Ltd.$191K
AbbVie$184K
LEO Pharma AS$62K
Astrazeneca UK Limited$49K
plus $98K from 4 others

What the payments were for

Consulting fees$565,40075%
Speaking & faculty fees$113,35615%
Travel & lodging$69,3289%
Food & beverage$6,5701%
Education$800%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	109	$311,142
LEO Pharma AS	30	$86,449
Sanofi-aventis U.S. LLC	21	$83,644
AbbVie	36	$27,656
UCB, Inc.	10	$24,630
Regeneron	12	$24,136
UCB SA	13	$22,926
Dermavant Sciences, Inc.	12	$17,683
LEO Pharma Inc.	5	$17,210
Regeneron Healthcare Solutions, Inc.	18	$16,891
Novartis	13	$16,558
Merck	16	$16,249
Janssen Global Services, LLC	3	$15,100
GSK	4	$13,897
Amgen	13	$12,029
Pfizer	6	$9,193
Incyte Corporation	4	$7,560
Mallinckrodt Hospital Products Inc.	1	$7,150
Astrazeneca UK Limited	5	$6,080
Galderma Laboratories, L.p.	6	$5,575
Janssen Research & Development, LLC	3	$5,200
Arcutis Biotherapeutics, Inc.	2	$3,750
Gilead	1	$1,660
AstraZeneca	4	$1,471
Almirall LLC	1	$525
Genentech USA, Inc.	2	$231
Blueprint Medicines Corporation	1	$104
Eli Lilly	1	$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$317,863
TAPINAROF$17,447
NO PRODUCT DISCUSSED$7,592
FASENRA$6,080
CIBINQO$5,840
EUCRISA$3,285
ZORYVE$1,500
Rinvoq$650
XOLAIR$231
AYVAKIT$104

How this compares

$754,734 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York →

Medicare billing

Part B allowed, 2024

$8,538

Medicare patients

Services billed

299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent SyringeDupilumab	22	$77,564
Dupixent PenDupilumab	19	$64,692
Ketoconazole	12	$49

Paid to pharmacies, not to this prescriber.

Other dermatology in Rochester

Alexandra GolantNew York$3.6M
David CohenNew York$3M
Michael CameronNew York$2.6M
Saakshi KhattriNew York$2.4M
Amy WechslerNew York$2.4M
Jeffrey WeinbergKew Gardens$2.3M
Joshua ZeichnerNew York$2.1M
Russell CohenOceanside$2.1M
Jeffrey LaducaAuburn$1.9M
Emma GuttmanNew York$1.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →